心力衰竭患者的SGLT2抑制剂:基于模型的元分析
Na Wang1, Zhen Wu1, Jianwei Ren1
1Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Clinical pharmacokinetics
|November 22, 2024
概括
在心力衰竭患者中,-葡萄糖共载体2 (SGLT2) 抑制剂有效降低N-终端亲B型尿素 (NT-proBNP). 卡纳格利弗洛辛显示最大的NT-proBNP减少,受基线水平,功能和体重的影响.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 心力衰竭 (HF) 是一种复杂的综合征,其特征是尿酸的升高.
- -葡萄糖共载体2 (SGLT2) 抑制剂正在成为治疗高血压的一类药物.
- N-终端亲B型性尿素 (NT-proBNP) 是HF管理中的一个关键生物标志物.
研究的目的:
- 量化SGLT2抑制剂对心力衰竭中NT-proBNP水平的影响.
- 分析共变体对SGLT2抑制剂降低NT-proBNP的疗效的影响.
- 为了比较不同SGLT2抑制剂的NT-proBNP降低作用.
主要方法:
- 对empagliflozin,dapagliflozin和canagliflozin的药理动力学 (PK) 和药理动力学 (PD) 数据的系统文献综述.
- 开发SGLT2抑制剂的群体PK模型和PK/PD周转模型.
- 使用开发的模型,模拟了52周的NT-proBNP变化.
主要成果:
- 在分析中包括了42个出版物.
- 基线NT-proBNP,估计的淋巴细胞过率 (eGFR) 和体重显著影响了SGLT2抑制剂的疗效.
- 与其他药物相比,卡纳格里弗洛辛在类似的基线水平上显示出优异的NT-proBNP降低.
结论:
- 基线NT-proBNP,功能和体重等共变量是SGLT2抑制剂降低NT-proBNP功效的关键决定因素.
- 在降低NT-proBNP方面,canagliflozin表现出最有利的结果.
- 基于模型的元分析方法为未来的SGLT2抑制剂药物开发提供了有价值的框架.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
01:26Heart Failure Drugs: Inotropic Agents
521
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
01:22Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343
01:22Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
01:27Glucose Transporters
22.5K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174